Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Journal of Clinical Investigation

Volumn 105, Issue 8, 2000, Pages

  Klement, Giannoula ^a   Baruchel, Sylvain ^b   Rak, Janusz ^a   Man, Shan ^a   Clark, Katherine ^a   Hicklin, Daniel J ^c   Bohlen, Peter ^c   Kerbel, Robert S ^a,d  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c ELI LILLY AND COMPANY   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VASCULARIZATION; XENOGRAFT;

EID: 0034087691     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI8829     Document Type: Article

References (55)

1. Folkman, J. 1972. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175:409-416.
2. Kerbel, R.S. 2000. Tumor angiogenesis: past, present, and the near future. Carcinogenesis. 21:505-515.
3. Ferrara, N., and Alitalo, K. 1999. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5:1359-1364.
4. Presta, L.G., et al. 1997. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 57:4593-4599.
5. Witte, L., et al. 1998. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17:155-161.
6. Prewett, M., et al. 1999. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human rumors. Cancer Res. 59:5209-5218.
7. Fong, T.A., et al. 1999. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-I/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59:99-106.
8. Lin, P., et al. 1997. Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. J. Clin. Invest. 100:2072-2078.
9. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M.S. 1997. Antiangiogenic therapy of experimental cancer does nor induce acquired drug resistance. Nature. 390:404-407.
10. Kaban, L.B., et al. 1999. Antiangiogenic therapy of a recurrent giant cell tumor of the mandible with interferon Alfa-2a. Pediatrics. 103:1145-1149.
11. Kerbel, R.S. 1991. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. BioEssays. 13:31-36.
12. Kerbel, R.S. 2000. Acquired drug resistance driven by tumor cell genetic instability: circumvention by direct acting anti-angiogenic vascular targeting agents. In DNA alterations in cancer: genetic and epigenetic changes. M. Ehrlich, editor. Biotechniques Books. Natick, MA. 489-501.
13. Gorski, D.H., et al. 1999. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 59:3374-3378.
14. Jain, R.K., et al. 1998. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent rumor: role of vascular endothelial growth factor. Proc. Natl. Acad. Sci. USA. 95:10820-10825.
15. Benjamin, L.E., Golijanin, D., Itin, A., Pode, D., and Keshet. E. 1999. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 103:159-165.
16. Denekamp, J. 1993. Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br. J. Radiol. 66:181-196.
17. Tannock, I.F. 1970. Population kinetics of carcinoma cells, capillary endothelial cells, and fibroblasts in a transplanted mouse mammary tumor. Cancer Res. 30:2470-2476.
18. Tannock, I.F., and Hayashi, S. 1972. The proliferation of capillary endothelial cells. Cancer Res. 32:77-82.
19. Belotti, D., et al. 1996.The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. 2:1843-1849.
20. O'Leary, J.J., et al. 1999. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin. Cancer Res. 5:181-187.
21. Baguley, B.C., Holdaway, K.M., Thomson, L.L., Zhuang, L., and Zwi, L.J. 1991. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer. 27:482-487.
22. Schirner, M., Hoffmann, J., Menrad, A., and Schneider, M.R. 1998. Antiangiogenic chemotherapeutic agents: characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin. Cancer Res. 4:1331-1336.
23. Frusta, M., et al. 1999, Purine analogue 6-merhylmercapropurine riboside inhibits early and late phases of the angiogenesis process. Cancer Res. 59:2417-2424.
24. Steiner, R. 1992. Angiostatic activity of anticancer agents in the chick embryo chorioallantoic membrane (CHE-CAM) assay. In Angiogenesis: key principles science technology medicine. R. Steiner, P.S. Weiss, and R. Langer, editors, Birkhauser Verlag, Basel, Switzerland. 449-454.
25. Yoshikawa, A., Saura, R., Matsubara, T., and Mizuno, K. 1997. A mechanism of cisplatin action: antineoplastic effect through inhibition of neovascularization. Kobe. J. Med. Sci. 43:109-120.
26. Browder, T., et al. 2000. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. In press.
27. Hirata, S., Matsubara, T., Saura, R., Tateishi, H., and Hirohata, K. 1989. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularization by low-dose methotrexate. Arthritis Rheum. 32:1065-1073.
28. Alon, T., et al. 1995. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1: 1024-1028.
29. Yuan, F., et al. 1996. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA. 93:14765-14770.
30. Strain, D.O., et al. 1996. (Consolidation chemoradiotherapy and autologous bone marrow transplantation versus continued chemotherapy for metastatic neuroblastoma: a report of two concurrent Children's Cancer Group studies. J. Clin. Oncol. 14:2417-2426.
31. Rockwell, P., Neufeld, G., Glassman, A., Caron, D., and Goldstem, N. 1995. In vitro neutralization of vascular endothelial growth factor activation of flk-1 by a monoclonal antibody. Mol. Cell. Different. 3:91-109.
32. Passaniti, A., et al. 1992. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:519-528.
33. Bordow, S.B., et al. 1994. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res. 54:5036-5040.
34. Jain, R.K. 1990. Vascular and interstitial barriers ro delivery of therapeutic agents in tumors. Cancer Metastasis Rev. 9:253-266.
35. Teicher, B.A., Sotomayor, E.A., and Huang, Z.D. 1992. Antiangiogenic agents potenriare cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 52:6702-6704.
36. Kakeji, Y., and Teicher, B.A. 1997. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest. New Drugs. 15:39-48.
37. Tashiro, T., et al. 1989. Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother. Pharmacol. 24:187-192.
38. Inaba, M., et al. 1989. Evaluation of antitumor activity in a human breast tumor/nude mouse model with a special emphasis on treatment dose. Cancer. 64:1577-1582.
39. Gerber, H.P., et al. 1998. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273:30336-30343.
40. Nor, J.E., Christensen, J., Mooney, D.J., and Polverini, P.J. 1999. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 154:375-381.
41. Tran, J., et al. 1999. Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem. Biophys. Res. Commun. 264:781-788.
42. O'Connor, D.S., et al. 2000. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 156:393-398.
43. LaCasse, E.C., Baird, S., Korneluk, R.G., and MacKenzie, A.E. 1998. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene. 17:3247-3259.
44. Tamm, I., et al. 1998. IAP-Family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 58:5315-5320.
45. Mauceri, H.J., et al. 1998. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature. 394:287-291
46. Vacca, A., et al. 1999. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 94:4143-4155.
47. Clements, M.K., Jones, C.B., Cumming, M., and Daoud, S.S. 1999. Antiangiogenic potential of camptothecin and topotecan. Cancer Chemother. Pharmacol. 44:411-416.
48. Vartanian, R.K., and Weidner, N. 1995. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab. Invest. 73:844-850.
49. Asahara, T., et al. 1999. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18:3964-3972.
50. Ito, H., et al. 1999. Endothelial progenitor cells as putative targets for angiostatin. Cancer Res. 59:5875-5877.
51. Slaton, J.W., Perrotte, P., Inoue, K., Dinney, C.P., and Fidler, I.J. 1999. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res. 5:2726-2734.
52. Hainswoith, J.D., Burris, H.A., Erland, J.B., Thomas, M., and Greco, F.A. 1998. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J. Clin. Oncol. 16:2164-2168.
53. Rocca, A., et al. 1999. Low dose oral Methotrexate (MTX) and Cyclophosphainide (CTX) in metastatic breast cancer (MBC): antitumor activity and correlation with serum vascular endothelial growth factor (VEGF) levels. Proc. Am. Soc. Clin. Oncol. 18:121a. (Abstr.)
54. McLeod, H.L., and Evans, W.E. 1999. Oral cancer chemotherapy: the promise and the pitfalls. Clin. Cancer Res. 5:2669-2671.
55. Lamont, E.B., and Schilsky, R.L. 1999. The oral fluoropyrimidines in cancer chemotherapy. Clin. Cancer Res. 5:2289-2296.